COMPANY PROFILE

Cibiem

Explore full profile

Cibiem - Restoring Sympathetic Balance

New York City, United StatesFounded 2012Biotech & Life Sciences

Valuation $50–100M Last recorded · 2012

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Cibiem

Cibiem is a medical device company that focuses on developing innovative therapies for diseases mediated by the sympathetic nervous system, such as hypertension, heart failure, and diabetes. The company leverages a proprietary, minimally invasive, catheter-based approach known as Carotid Body Modulation (CBM) to treat these conditions. Cibiem serves patients suffering from chronic cardiovascular and metabolic diseases, operating primarily in the medical technology and healthcare markets. The business model is centered around the development and commercialization of its unique medical devices, generating revenue through product sales and potentially through partnerships or licensing agreements. The company is backed by prominent venture investors, including Third Rock Ventures and SV Life Sciences, which underscores its strong financial foundation and growth potential.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: New York City, United States
Employees: 1
Open positions: None listed
Dealroom signal: 50.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Cardiology and cardiovascular, Non-Invasive medical devices and treatments, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBT✓Debt	Oct 2016	$0	—	SV Health Investors	—
SERIES B✓Equity / VC	Feb 2016	—	—	SV Health Investors	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Cibiem website traffic

Latest recorded traffic for Cibiem is 2K monthly website visits, up 1011.1% over the last three months. Cibiem's team grew 0% over the past year.

Latest monthly visits2K 3-month web change+1011.1% 1-year team growth0%

Monthly website visitsApr 2016–Apr 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MLMedGenome LabsA genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome	Foster City, United States	Operational	1,013	$233M	$275M
APAEGLE PaletteDigital Therapeutic Platform, Lifestyle Data and Behavior Intervention as a Service	San Francisco, United States	Operational
MNMedCity NewsMedCity News - Healthcare technology news, life science current eventsMedCity News	New York City, United States	Operational
RIRimidiRimidi- Serious Hope for Healthcare	Atlanta, United States	Acquired
OPOmthera PharmaceuticalsDevelops therapies for patients with elevated triglyceride levels and increased risk of cardiovascular disease	Princeton, United States	Acquired
ENEnteroMedicsTips and tricks for quitting smoking	Saint Paul, United States	Operational
SPSynta PharmaceuticalsInnovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients	Lexington, United States	Acquired
FIFitgenesAustralian organization that delivers personalized, genome-based health and wellness programs	Brisbane, Australia	Operational